Can CAR-T Finally Treat Stomach and Pancreatic Cancer? A 2024 Trial

CAR-T therapy has been a genuine revolution — for blood cancers. Against solid tumours, it has mostly hit a wall, which is why stomach and pancreatic cancer have remained among the hardest to treat. So a 2024 trial reporting that CAR-T cells could shrink these tumours in a meaningful share of patients is a real signal worth understanding — neither dismissing it nor overselling it ¹.

Pancreatic cancer in particular has resisted almost everything thrown at it, so any credible progress deserves a careful, honest look.

What question did the researchers ask?

The researchers asked whether CAR-T cells engineered to target a protein called Claudin18.2 could safely shrink advanced gastrointestinal cancers — mainly gastric (stomach) and pancreatic cancers — in patients who had already exhausted standard treatments ¹.

The choice of target is the clever part. One reason CAR-T struggles with solid tumours is the lack of a good target — a protein that's on the cancer but not on healthy tissue. Claudin18.2 is appealing because it appears on many gastric and pancreatic cancer cells. The engineered cells, called CT041, are built to recognise that protein and attack the cells carrying it. If CAR-T itself is unfamiliar, our explainer on CAR-T therapy covers the basics, and our piece on a glioblastoma CAR-T trial shows the same solid-tumour challenge in the brain.

What did the trial find?

This was an early-phase (phase 1) trial, so it was designed mainly to test safety — but the activity signal was unusually strong for these cancers. Roughly half of treated patients saw their tumours shrink (an overall response rate near 49% in the earlier analysis), and a clear majority had at least disease control ¹. In advanced, heavily pre-treated gastric and pancreatic cancer, where responses are normally rare, that is a striking result.

On safety, the main side effect was cytokine release syndrome (CRS) — the immune-activation reaction familiar from CAR-T — but in the early data it was mostly mild to moderate, with no severe (grade 3 or higher) CRS or neurotoxicity reported ¹. That relatively manageable safety profile, combined with real responses, is what generated the excitement.

How strong is this evidence?

It's early but meaningful. A phase 1 trial can't tell us how long responses last, how the therapy performs in larger groups, or how it compares with standard care — and a response (tumour shrinkage) is not the same as a cure or proven longer survival. There's also a specific challenge to watch with this target: Claudin18.2 is present at low levels in the healthy stomach lining, so "on-target, off-tumour" effects need careful monitoring as trials grow.

Still, context makes this stand out. CAR-T has produced very few wins in solid tumours, and gastric and especially pancreatic cancer are notoriously treatment-resistant. A roughly 50% response rate in that setting — with manageable early safety — is exactly the kind of signal that justifies larger trials and real optimism, while staying short of "proven".

What could this mean if you are considering treatment?

For patients with advanced gastric or pancreatic cancer, this is encouraging news about the direction of treatment — but it remains experimental and trial-based, not an approved option you can simply request. The sensible step is to ask an oncology team whether any Claudin18.2 CAR-T (or similar) trials are open and appropriate, and what the realistic goals and risks would be.

As always, be cautious of anyone marketing "CAR-T for pancreatic cancer" outside a legitimate trial or specialist centre — the evidence describes early-phase research at experienced sites, not a ready therapy.

What we see at the clinic

When people ask us whether cell therapies can help solid cancers like stomach or pancreatic cancer, we point to results like this as genuine, hard-won progress — and we're equally clear that it's early-stage and belongs in proper trials and cancer centres. The honest message is optimistic but precise: CAR-T is finally showing real signs of life against some of the toughest solid tumours, and that's worth following closely while keeping expectations grounded.

Common questions

Does this cure stomach or pancreatic cancer? No. About half of heavily pre-treated patients had tumour shrinkage ¹ — a strong signal for these cancers — but it's an early-phase trial, not proof of cure or longer survival.

Why is this a big deal if it's only phase 1? Because CAR-T has rarely worked against solid tumours at all, and gastric and pancreatic cancers are especially hard to treat. A roughly 50% response rate here is genuinely notable.

Can I get Claudin18.2 CAR-T now? Not as standard care — it's investigational, available through clinical trials at specialist centres, not yet an approved treatment.

[1] Claudin18.2-specific CAR T cells (CT041) in gastrointestinal cancers: phase 1 trial final results. Nature Medicine. 2024. https://doi.org/10.1038/s41591-024-03037-z

Key takeaway

A 2024 trial showed that CAR-T cells aimed at Claudin18.2 shrank tumours in roughly half of patients with advanced gastric and pancreatic cancer — an unusually strong signal in solid tumours that CAR-T usually can't touch, with mostly manageable early side effects. It's still an early-phase, unapproved therapy with real questions ahead, but it's one of the most promising signs yet that CAR-T can break into solid-tumour territory.